The nation's largest publicly traded real estate investment trusts specializing in the life sciences offered chillier forecasts this year in the US for signing tenants to new leases, renewing existing ones, or breaking ground on new projects as landlords and tenants continue to feel the effects of the ongoing financial downturn.

In separate conference calls last week, top executives from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP cautioned that life-science companies are increasingly skittish about leasing new space for the long term.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.